ORI Capital builds up new $260 million fund for biotech

23 February 2024

Sino-American healthcare-focused venture capital firm ORI Capital has announced the final close of its second fund.

ORI Fund II has raised $260 million for the firm, which was founded in 2015 and is led by veteran investor, Simone Song.

"We are in a golden era of innovation across the intersection of AI and biology"The fund will invest in innovative early-stage biotech companies globally, across the areas of diagnostics, drug delivery, and therapeutics focused on areas of significant unmet medical need with the highest mortality rates such as cancer, metabolic disorders and neurodegenerative diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK